Journals Expert Review of Clinical Immu...

Expert Review of Clinical Immunology
Akihiro Nakamura, Vinod Chandran
No abstract text is available yet for this article.
September 29, 2023: Expert Review of Clinical Immunology
Aikaterini Anagnostou, Antonella Muraro
No abstract text is available yet for this article.
September 27, 2023: Expert Review of Clinical Immunology
Raha Zamani, Nima Rezaei
INTRODUCTION: Head and neck squamous cell carcinomas (HNSCC) have increasing incidence, high recurrence and overall unfavorable prognosis despite numerous treatment options. The distinct immune landscape of HNSCC suggests a potential for immune-related biomarkers to aid classification and treatment planning. AREAS COVERED: Immunoscore, a multiplex measure of tumor-infiltrating immune cells is currently approved in colorectal carcinoma and is under investigation in various other cancer types...
September 26, 2023: Expert Review of Clinical Immunology
Ahmad Z Al Meslamani
No abstract text is available yet for this article.
September 23, 2023: Expert Review of Clinical Immunology
Huihua Ding, Yiwei Shen, Soon-Min Hong, Chunyan Xiang, Nan Shen
INTRODUCTION: Systemic lupus erythematosus (SLE) is complex autoimmune disease with heterogenous manifestations, unpredictable disease course and response to treatment. One of the critical needs in SLE management is the identification of reliable biomarkers that can aid in early diagnosis, accurate monitoring of disease activity, and assessment of treatment response. AREAS COVERED: In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment...
September 15, 2023: Expert Review of Clinical Immunology
Naim Mahroum, Ravend Seida, Yehuda Shoenfeld
INTRODUCTION: Rheumatoid arthritis is a chronic inflammatory disease marked by systemic symptoms and joint degeneration. Interestingly, the development and progression of rheumatoid arthritis have been linked to the microbiome, notably the gut microbiome. Dysbiosis, an alteration in the gut microbiome, has been connected to the etiology and pathogenesis of rheumatoid arthritis. For instance, dysbiosis increases intestinal permeability and promotes the movement of bacteria and their products, which in turn triggers and aggravates systemic inflammation...
September 15, 2023: Expert Review of Clinical Immunology
Shengnan Cui, Bingjie Zhang, Li Li
INTRODUCTION: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder in older adults. There is increasing evidence that BP has connections with renal diseases, such as glomerulopathy and neoplasm; it is also linked to the receipt of renal replacement therapy. AREAS COVERED: In this review, we summarize the current evidence that BP is a comorbidity of common renal diseases. Furthermore, our exploration of the characteristics and possible mechanisms underlying these connections provides insights that may facilitate the prevention, diagnosis, and management of BP...
September 14, 2023: Expert Review of Clinical Immunology
Elena Treppo, Luca Quartuccio, Salvatore De Vita
INTRODUCTION: Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a systemic vasculitis that affects small blood vessels. It exhibits a wide range of clinical manifestations, making its treatment a continuing challenge for physicians. AREAS COVERED: We conducted a comprehensive review to evaluate the current status of diagnosis, management, and treatment of mixed cryoglobulinemia (MC). The accurate clinical and serological evaluation plays a vital role in diagnosing MC, identifying potential comorbidities, and monitoring its main manifestations and complications...
September 12, 2023: Expert Review of Clinical Immunology
Uwe Klaus Zettl, Paulus Stefan Rommer, Orhan Aktas, Torsten Wagner, Joachim Richter, Patrick Oschmann, Lukas Cepek, Birte Elias-Hamp, Klaus Gehring, Andrew Chan, Michael Hecker
INTRODUCTION: Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment. AREAS COVERED: Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses...
September 11, 2023: Expert Review of Clinical Immunology
Kate Tokareva, Pankti Reid, Victor Yang, David Liew, Alexander C Peterson, Aaron Baraff, Jon Giles, Namrata Singh
INTRODUCTION: Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune and myeloproliferative disorders. Recently, concern has arisen regarding their safety in patients with rheumatoid arthritis. AREAS COVERED: Here, we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on comparative safety, and provide insight into their future and use. We emphasize that the application of the research findings on a case-by-case basis should consider a patient's age, comorbidities, disease for which JAKi is being considered, disease activity, the JAKi target(s), alternate treatment options available for the patient, and the planned duration of JAKi...
September 4, 2023: Expert Review of Clinical Immunology
Kiarash Saleki, Mohamad Hosein Mohamadi, Parsa Alijanizadeh, Nima Rezaei
INTRODUCTION: Chimeric antigen receptor (CAR) T-cell is among the most prevalent approaches that act by directing T-cells toward cancer; however, they need to be optimized to minimize side effects and maximize efficacy before being used as standard treatment for malignancies. Neurotoxicity associated with CAR T-cell therapy has been well-documented in recent works. AREAS COVERED: In this regard, two established syndromes exist. Immune effector cell-associated neurotoxicity syndrome (ICANS), previously called cytokine release encephalopathy syndrome (CRES), is a neuropsychiatric condition which can occur after therapy by immune effector cells (IEC) and T-lymphocytes utilizing treatments...
September 4, 2023: Expert Review of Clinical Immunology
Lluís Rusiñol, Elena Carmona-Rocha, Lluís Puig
INTRODUCTION: Significant advances in psoriasis treatment have taken place since the introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics approved and at that time greatly improved psoriasis treatment. However, newer biologics, directed to interleukin(IL)-23/IL-17 pathways central to psoriasis pathogenesis,have improved complete or nearly complete clearance rates and are characterized by an excellent safety profile.Real-world setting experiences have generally confirmed the results of clinical trials, but real-world data regarding newer biologics is relatively scarce...
August 23, 2023: Expert Review of Clinical Immunology
Mattia Algeri, Marco Becilli, Franco Locatelli
INTRODUCTION: Acute and chronic graft-versus-host disease (GvHD) are potentially life-threatening complications occurring after allogeneic stem cell transplantation (allo-HSCT). Although steroids represent the first-line treatment for both conditions, in those patients who do not adequately benefit from steroid therapy, standardized treatment algorithms are lacking. In recent years, ruxolitinib has emerged as the most promising agent for the second-line therapy of steroid-refractory (SR)-GvHD...
August 22, 2023: Expert Review of Clinical Immunology
Rubén Queiro, Marta Loredo, Ignacio Braña, Estefanía Pardo, Sara Alonso, Mercedes Alperi
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic, immune-mediated disease characterized by synovio-entheseal inflammation. It is estimated to affect around 30% of patients with psoriasis and significantly reduces patients' physical function and quality of life. There is a growing number of treatment options for PsA, but due to the heterogeneous clinical features of the disease and prevalence of comorbidities, managing PsA can be challenging. AREAS COVERED: In this article, we review current understanding of the disease and available pharmacological options...
August 21, 2023: Expert Review of Clinical Immunology
Koshiro Sonomoto, Yoshiya Tanaka
INTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune disorder necessitating immunosuppressive therapy. Remarkable progress has been made in the treatment of RA over recent decades, particularly with the development of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). Nonetheless, the development of new drugs has been accompanied by concerns regarding the association between these novel therapies and the risk of malignancy. AREAS COVERED: This narrative review aims to discuss the understanding of RA, conventional synthetic (cs) DMARDs, bDMARDs, JAKi, and their association with malignancy...
August 14, 2023: Expert Review of Clinical Immunology
(no author information available yet)
No abstract text is available yet for this article.
August 14, 2023: Expert Review of Clinical Immunology
Mariam Saad, Ella Castellano, Ahmad A Tarhini
INTRODUCTION: Locoregionally advanced melanoma represents a large group of high-risk melanoma patients at presentation and poses major challenges in relation to management and the risks of relapse and death. AREAS COVERED: Melanoma systemic therapy has undergone substantial advancements with the advent of immune checkpoint inhibitors and molecularly targeted therapies, which have been translated to the neoadjuvant setting for the management of locoregionally advanced disease...
August 14, 2023: Expert Review of Clinical Immunology
Philip J Smith, Mathurin Fumery, Rupert W Leong, Kerri Novak, Axel Dignass
INTRODUCTION: The first subcutaneous (SC) formulation of infliximab (IFX), CT‑P13 SC, has been approved in Europe and Australia, including for the treatment of inflammatory bowel disease (IBD). AREAS COVERED: We provide a comprehensive overview of available clinical trial and real-world data for IFX SC treatment of IBD, focusing on the potential benefits of switching from IFX intravenous (IV) to IFX SC. We evaluate emerging evidence for IFX SC treatment for difficult-to-treat IBD, use as monotherapy, and suitability for patients receiving escalated IFX IV doses...
August 13, 2023: Expert Review of Clinical Immunology
Xian Li, Jingyun Li, Xu Xu, Wenyu She, Chengshuo Wang, Yuan Zhang, Luo Zhang
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a common and challenging clinical entity, and its economic burden has not been well described in China thus far. METHODS: A total of 101 CRSwNP patients who underwent endoscopic sinus surgery were included to investigate direct costs in the first year post-surgery. Costs for outpatient visits, medication use, and examination costs were obtained from the Hospital Information System, and differences were compared between subgroups...
August 9, 2023: Expert Review of Clinical Immunology
M A Slatter, M A Maschan, A R Gennery
INTRODUCTION: Hematopoietic stem cell transplantation is a curative treatment for many inborn errors of immunity (IEI). Incremental improvements and advances in care have led to high rates of >85% survival and cure in many of these diseases. Improvements in HLA-classification and matching have led to increased survival using HLA-matched donors, but survival using T-lymphocyte-depleted mismatched grafts remained significantly worse until fairly recently. Advances in T-lymphocyte depletion methods and graft engineering, although not specific to IEI, have been widely adopted and instrumental in changing the landscape of donor selection, such that a donor should now be possible for every patient...
August 9, 2023: Expert Review of Clinical Immunology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.